Limits...
Dopamine supersensitivity psychosis and dopamine partial agonist: a retrospective survey of failure of switching to aripiprazole in schizophrenia.

Takase M, Kanahara N, Oda Y, Kimura H, Watanabe H, Iyo M - J. Psychopharmacol. (Oxford) (2015)

Bottom Line: We conducted a retrospective investigation for 264 patients whose treatment medication was switched to ARI from other antipsychotics.We divided the patients into the DSP(+) group with a history of DSP episode(s) (N = 70) and the DSP(-) group without such a history (N = 194), and then compared the clinical factors relevant to the success or failure of the switch to ARI between them.Our findings suggest that patients who receive high dosages of antipsychotic drugs form overt or covert DSP and such state is highly associated with psychotic worsening following ARI treatment.

View Article: PubMed Central - PubMed

Affiliation: Department of Psychiatry, Chiba University Graduate School of Medicine, Chiba, Japan.

No MeSH data available.


Related in: MedlinePlus

Distribution of clinical outcome following aripiprazole treatment in the DSP(+) and DSP(–) groups.
© Copyright Policy - open-access
Related In: Results  -  Collection

License 1 - License 2 - License 3
getmorefigures.php?uid=PMC4363127&req=5

fig2-0269881115570083: Distribution of clinical outcome following aripiprazole treatment in the DSP(+) and DSP(–) groups.

Mentions: In the DSP(+) group, the rates of CON, D-OTH and D-POS were 20%, 57% and 23%, respectively, whereas these values were 52%, 40% and 8% in the DSP(–) group (Figure 2), with a significant difference in the distribution between the two groups (P < 0.01). This result indicated that the discontinuation ratio of ARI and the worsening ratio in the DSP(+) group were significantly higher than those in the DSP(–) group.


Dopamine supersensitivity psychosis and dopamine partial agonist: a retrospective survey of failure of switching to aripiprazole in schizophrenia.

Takase M, Kanahara N, Oda Y, Kimura H, Watanabe H, Iyo M - J. Psychopharmacol. (Oxford) (2015)

Distribution of clinical outcome following aripiprazole treatment in the DSP(+) and DSP(–) groups.
© Copyright Policy - open-access
Related In: Results  -  Collection

License 1 - License 2 - License 3
Show All Figures
getmorefigures.php?uid=PMC4363127&req=5

fig2-0269881115570083: Distribution of clinical outcome following aripiprazole treatment in the DSP(+) and DSP(–) groups.
Mentions: In the DSP(+) group, the rates of CON, D-OTH and D-POS were 20%, 57% and 23%, respectively, whereas these values were 52%, 40% and 8% in the DSP(–) group (Figure 2), with a significant difference in the distribution between the two groups (P < 0.01). This result indicated that the discontinuation ratio of ARI and the worsening ratio in the DSP(+) group were significantly higher than those in the DSP(–) group.

Bottom Line: We conducted a retrospective investigation for 264 patients whose treatment medication was switched to ARI from other antipsychotics.We divided the patients into the DSP(+) group with a history of DSP episode(s) (N = 70) and the DSP(-) group without such a history (N = 194), and then compared the clinical factors relevant to the success or failure of the switch to ARI between them.Our findings suggest that patients who receive high dosages of antipsychotic drugs form overt or covert DSP and such state is highly associated with psychotic worsening following ARI treatment.

View Article: PubMed Central - PubMed

Affiliation: Department of Psychiatry, Chiba University Graduate School of Medicine, Chiba, Japan.

No MeSH data available.


Related in: MedlinePlus